BRIEF—ImmunoPrecise to acquire ModiQuest Research

Canada’s ImmunoPrecise (IPA) has signed a binding letter of intent to acquire Netherlands-based ModiQuest Research.

The transaction continues to realize on the board's commitment to grow globally through strategic acquisitions.

It allows IPA to become a single source provider of services across the full antibody discovery value chain (antigen design, hit generation, lead selection, lead optimization and lead characterization) and to offer the full spectrum of antibody production methodologies (library based technologies, hybridoma methods, transgenic animal based platforms and single B cell based technology).

Furthermore, the acquisition, financial terms of which were not disclosed, enhances the company's capacity for generating human antibodies.

"In acquiring ModiQuest Research BV, IPA becomes a leading integrated antibody solutions company with global reach," said Dr James Kuo, chairman, interim president of ImmunoPrecise.